Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well. | Main | By Any Other Name »

July 15, 2002

The Apatosaurus. The Spruce Goose. The Pyramids

Email This Entry

Posted by Derek

The news this morning is full of the Pfizer/Pharmacia (aka Pharmacia-Upjohn) merger. Perhaps this will trigger the long-expected wave of further drug company consolidation (but, then again, the Pfizer/Warner-Lambert deal was supposed to do that, too.)

I hope it doesn't, but I have to admit that the industry is congealing, and has been for some years. One way or another, we seem to be heading for a world of three or four really humungous pharmaceutical companies in the US, maybe six or eight worldwide. It's not a situation I find very appealing, for many reasons.

Philosophically, I prefer having a multitude of companies, because that seems to be the best way to take a number of approaches to drug discovery. Scientifically speaking, the competition, which can come from anywhere, keeps everyone on their toes and keeps the research moving along. Aesthetically, I doubt if I'd enjoy the atmosphere of MegaPharmaConsoliCorp. Think of its HR department, and the budget they'd have!

And practically, fewer drug companies mean fewer places for people like me, and my colleagues and friends, to work. It's bad enough when a Bristol-Meyers Squibb goes through a bad patch and stops hiring (or starts firing.) What if there are only three big companies, and one or two of them go through a hiring freeze?

It's a real possibility. I've seen nothing to convince me that bigger is all that better in this industry. Small isn't fun, smaller than the giants is hard - but that doesn't have any bearing on what it's like to be a giant. We still don't know how to reliably crank out the wonder drugs, no matter how big the company. Or its HR department.

Comments (0) + TrackBacks (0) | Category: Business and Markets


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi
Total Synthesis in Flow
Sweet Reason Lands On Its Face